Trillium Therapeutics buy melinda
Start price
03.04.17
/
50%
€5.85
Target price
04.04.17
€6.12
Performance (%)
5.81%
End price
04.04.17
€6.19
Summary
This prediction ended on 04.04.17 with a price of €6.19. The BUY prediction by melinda finished with a performance of 5.81%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Trillium Therapeutics | - | - | - | - |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% | 68.627% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% | 116.238% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% | 56.217% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% | 70.924% |
Comments by melinda for this prediction
In the thread Trillium Therapeutics diskutieren
ONKOLOGIE
TORONTO, ONTARIO - (Marketwire - 3. April 2017) - Trillium Therapeutics Inc. ( TRIL ) ( TRIL ) klinische Immun-Onkologie - Unternehmen die Entwicklung innovativer Medikamente für die Behandlung von Krebs im Stadium, Aktualisierungen werden heute und präklinische Tag folgende klinisch auf seinem TTI-621 - Programm
Stopped prediction by melinda for Trillium Therapeutics
Trillium Therapeutics
Start price
Target price
Perf. (%)
€3.94
24.01.20
24.01.20
€15.00
04.11.21
04.11.21
287.94%
05.11.21
05.11.21
Trillium Therapeutics
Start price
Target price
Perf. (%)
€8.70
18.11.17
18.11.17
€13.08
18.05.18
18.05.18
-37.82%
18.05.18
18.05.18
Trillium Therapeutics
Start price
Target price
Perf. (%)
€0.90
03.10.10
03.10.10
€3.60
04.04.11
04.04.11
1133.33%
04.04.11
04.04.11